Oct 2026· Radiotherapy and Oncology· Vol 226, pp.
111818
· 0 citations· 44 references
Medicine
TL;DR
Regular post-treatment surveillance, particularly distant imaging, could improve NPC survival, highlighting an urgency for evidence-based post-treatment surveillance strategies.
Abstract
Purpose
Benefit of post-treatment surveillance in nasopharyngeal carcinoma (NPC), characterized by high recurrence risk, remains unexplored. We explored whether regular post-treatment surveillance facilitates earlier recurrence detection and improves survival.
Methods
AND MATERIALS
We identified 8,798 patients with non-metastatic stage I-IVA NPC at Sun Yat-sen University Cancer Center. The 1-year landmark analysis was chosen as representative of surveillance patterns, dividing patients into regular and irregular surveillance group based on surveillance intensity. Cox proportional hazards models clarified the association between overall survival (OS) and surveillance intensity, with subgroup analyses stratified by clinical stage and pretreatment Epstein-Barr virus DNA level. Survival impact of surveillance imaging for local, regional, and distant sites were also investigated.
Results
Median follow-up was 64.8 months. 1-year landmark analysis comprised 4,078 and 4,720 patients receiving regular (≥ 4 visits in the first year) and irregular surveillance (< 4 visits), respectively. Regular surveillance was linked to shorter median recurrence time (26.1 versus 27.0 months) and improved OS (HR, 0.86; 95% CI, 0.74-0.99; P = 0.032) after multivariable adjustment. Notably, patients receiving regular imaging surveillance for distant site had better OS (HR, 0.69; 95% CI, 0.57-0.82; P < 0.001) whereas imaging for local (HR, 1.36; 95% CI, 0.90-2.04; P = 0.140) and regional site (HR, 0.85; 95% CI, 0.57-1.27; P = 0.428) did not. Regular surveillance patients with distant metastases exhibited fewer metastatic organs (P < 0.001) and earlier recurrence stages (P < 0.001), translating into prolonged post-recurrence survival (HR, 0.68; 95% CI, 0.58-0.80; P < 0.001).
Conclusions
Regular post-treatment surveillance, particularly distant imaging, could improve NPC survival, highlighting an urgency for evidence-based post-treatment surveillance strategies.
The method demonstrated acceptable safety and efficacy results; however, continued follow-up is necessary to determine long-term outcomes, as the method demonstrated acceptable safety and efficacy results.
A. M. Pozharytski, Y. A. Poddubny, M. L. Parmon et al.· Cancer Urology· 0 citations
OBJECTIVE
To evaluate the impact of diagnosis-to-treatment interval (DTI) and radiotherapy interval (RTI) on overall survival (OS) in locally advanced nasopharyngeal carcinoma (LA-NPC) treated with concurrent chemoradiotherapy (CCRT).
STUDY DESIGN
Retrospective database study.
SETTINGS
Single tertiary academic cent...
E. Topkan, E. Somay, S. Başçıl et al.· Otolaryngology Head & Neck S...· 0 citations
OBJECTIVE
This study aimed to investigate the potential benefit of survival of receiving timely postoperative radiation therapy (PORT) for head and neck cancer.
STUDY DESIGN
Retrospective cohort.
SETTING
National Cancer Database from 2004 to 2020.
METHODS
Patients with a diagnosis of human papilloma virus (HPV)-n...
Peter Q. Luong, Alexis L. Hartman, Lisa Vélez-Vélez et al.· Otolaryngology Head & Neck S...· 0 citations
The results show that surveillance protocols should be individualized, in which the intensity and duration of follow-up are based on the risk of BCR and OCM according to individual recurrence risk and competing mortality.
F. Pellegrino, U. Falagario, A. Abbadi et al.· European Urology Oncology· 0 citations
AIM
To evaluate postoperative progression-free survival (PFS), identify clinicopathological factors associated with PFS, and explore the association between postoperative adjuvant therapy and PFS after surgery for urachal carcinoma.
METHODS
We retrospectively included 72 patients with histopathologically confirmed ma...
Hong-Yu Zhang, Ze-Xuan Lv, Zi-Jian Wang et al.· Urologic oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.